Replimune

Replimune is a clinical-stage biotechnology company that develops oncolytic immunotherapies based on its proprietary RPx platform, which uses engineered herpes simplex virus. Its mission is to transform the lives of cancer patients with oncolytic immunotherapies. Its lead product candidate is vusolimogene oderparepvec (RP1), which is being developed for melanoma and other solid tumors. The company also has RP2 and other candidates in development.